Potential treatment for brain cancer as drug shrinks tumours

August 14, 2017, University of Queensland
Potential treatment for brain cancer as drug shrinks tumours
L-R: Dr Amanda Millar, Dr Laura Genovesi and Professor Brandon Wainwright. Credit: University of Queensland

An international team of researchers has found a drug previously approved to treat breast cancer could also be used to shrink medulloblastoma, a common form of childhood brain tumour.

The discovery, made by The University of Queensland's Institute for Molecular Bioscience and the Fred Hutchinson Cancer Research Center in Seattle, has led to a clinical trial using the drug palbociclib to treat children with , the most common malignant brain found in children.

UQ's Professor Brandon Wainwright said were the most common cause of cancer death in infants, children and adolescents – and even survivors can end up with significant long-term side effects from existing treatments.

"Clearly, we need new therapies that increase survival of young patients and reduce the side effects they suffer, such as delays in brain development, growth problems and increased risk of other cancers," Professor Wainwright said.

Fellow UQ researcher Dr Laura Genovesi examined the genetic code of medulloblastoma to predict whether these tumours may respond to already-approved drugs.

"This analysis led us to believe that palbociclib, an oral approved in 2015 for the treatment of , would be effective against medulloblastoma," Dr Genovesi said.

"We expected that palbociclib would arrest the growth of medulloblastoma, but we were stunned to find that it went a step further and actually shrank the tumours to a size where survival is possible."

"The finding is remarkable since the tumours were very advanced and were treated for only a short period of time and we did not use any other therapy such as chemotherapy in combination.

"Some tumours recurred once treatment with palbociclib stopped, probably due to resistant cells within the tumour.

"It means that palbociclib, or drugs like it, could be used against medulloblastoma in combination with other drugs to treat resistant cells.

"If the clinical trial is successful, it would represent a major step forward to taking this research from the genome to the clinic."

The study is published in the journal Clinical Cancer Research.

Explore further: Study reveals genes behind brain tumours

More information: Michelle L Cook Sangar et al. Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models, Clinical Cancer Research (2017). DOI: 10.1158/1078-0432.CCR-16-2943

Related Stories

Study reveals genes behind brain tumours

October 31, 2013
A team of researchers has pinpointed a handful of genes that could drive the formation of medulloblastoma, the most aggressive and frequent form of brain tumour found in children.

New insight into life-threatening childhood brain cancer

May 22, 2017
The most common type of malignant childhood brain cancer has been identified as seven separate conditions each needing a different treatment, new research has revealed.

Improving the survival rates of childhood brain tumours: Translating Discoveries

July 13, 2017
The future of children with brain tumours is very promising. To do nothing is to ignore the very real possibility of a treatment and cure. It is the time now to accelerate clinical and laboratory research in childhood brain ...

Stem cells may speed up screening of drugs for rare cancers

August 2, 2016
Researchers at the Johns Hopkins Kimmel Cancer Center say they have developed a system that uses transformed human stem cells to speed up screening of existing drugs that might work against rare brain and other cancers.

Scientists map out how childhood brain tumors relapse

December 18, 2014
Researchers have discovered the unique genetic paths that the childhood brain tumour medulloblastoma follows when the disease comes back, according to research published in Cancer Cell today.

Study shows biomarkers can predict which ER-positive breast cancer patients respond best to first-line therapy

June 27, 2017
Two challenges in treating patients with estrogen-positive breast cancer (ER+) have been an inability to predict who will respond to standard therapies and adverse events leading to therapy discontinuation. A study at The ...

Recommended for you

'Liquid biopsy' predicts lymphoma therapy success within days, study finds

August 20, 2018
A blood test can predict which patients with a type of cancer called diffuse large B cell lymphoma are likely to respond positively to initial therapy and which are likely to need more aggressive treatment, according to a ...

Study shows how to make (and destroy) a metastatic cancer cell

August 20, 2018
Many cancers become especially dangerous only when they metastasize from their site of origin to faraway tissues such as lung, brain or bone. Now, a University of Colorado Cancer Center study published today in the Proceedings ...

Research team develops predictor for immunotherapy response in melanoma

August 20, 2018
In a new study, researchers developed a gene expression predictor that can indicate whether melanoma in a specific patient is likely to respond to treatment with immune checkpoint inhibitors, a novel type of immunotherapy. ...

Study details effect of radiation exposure on hormone deficiencies

August 20, 2018
In a new study, University of Cincinnati (UC) researchers, in collaboration with Massachusetts General Hospital, have detailed the effect of radiation exposure on the development of hormone deficiency in pediatric and young ...

Scientists discover new method of diagnosing cancer with malaria protein

August 17, 2018
In a spectacular new study, researchers from the University of Copenhagen have discovered a method of diagnosing a broad range of cancers at their early stages by utilising a particular malaria protein that sticks to cancer ...

Researchers find pathways that uncover insight into development of lung cancer

August 17, 2018
Lung cancer is the leading cause of preventable cancer death. A disease of complex origin, lung cancer is usually considered to result from effects of smoking and from multiple genetic variants. One of these genetic components, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.